 Enrique Alvarez
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 38 | 2025 | 435 | 8.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 11 | 2024 | 73 | 2.520 |
Why?
| | Immunologic Factors | 7 | 2020 | 227 | 2.490 |
Why?
| | Fingolimod Hydrochloride | 6 | 2020 | 36 | 2.320 |
Why?
| | Natalizumab | 5 | 2023 | 40 | 2.250 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 6 | 2023 | 26 | 2.160 |
Why?
| | Rituximab | 6 | 2023 | 162 | 1.780 |
Why?
| | Immunosuppressive Agents | 9 | 2024 | 682 | 1.420 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 11 | 1.020 |
Why?
| | Agammaglobulinemia | 2 | 2023 | 33 | 1.020 |
Why?
| | Neuromyelitis Optica | 4 | 2020 | 128 | 0.730 |
Why?
| | Serum Sickness | 1 | 2019 | 6 | 0.660 |
Why?
| | Medical Marijuana | 1 | 2018 | 106 | 0.530 |
Why?
| | Pregnancy Complications | 2 | 2018 | 487 | 0.530 |
Why?
| | Lymphocyte Depletion | 3 | 2021 | 129 | 0.510 |
Why?
| | Axons | 2 | 2014 | 188 | 0.500 |
Why?
| | Marijuana Smoking | 1 | 2018 | 239 | 0.480 |
Why?
| | Oligoclonal Bands | 1 | 2014 | 20 | 0.470 |
Why?
| | Neurofilament Proteins | 1 | 2014 | 43 | 0.460 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2023 | 754 | 0.450 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 997 | 0.430 |
Why?
| | Anemia | 1 | 2015 | 160 | 0.430 |
Why?
| | Biomarkers | 3 | 2023 | 3874 | 0.420 |
Why?
| | Chemokine CXCL13 | 1 | 2013 | 6 | 0.420 |
Why?
| | Humans | 53 | 2024 | 128020 | 0.410 |
Why?
| | Recurrence | 6 | 2024 | 993 | 0.410 |
Why?
| | Adult | 26 | 2024 | 35177 | 0.400 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 1354 | 0.370 |
Why?
| | Middle Aged | 25 | 2024 | 30813 | 0.360 |
Why?
| | Female | 32 | 2025 | 68017 | 0.330 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1921 | 0.320 |
Why?
| | Brain | 7 | 2021 | 2615 | 0.310 |
Why?
| | Magnetic Resonance Imaging | 8 | 2022 | 3371 | 0.300 |
Why?
| | Walking | 4 | 2023 | 495 | 0.290 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 18 | 0.290 |
Why?
| | Demyelinating Diseases | 3 | 2025 | 84 | 0.280 |
Why?
| | Male | 28 | 2025 | 62758 | 0.280 |
Why?
| | Antigens, CD20 | 2 | 2023 | 27 | 0.260 |
Why?
| | B-Lymphocytes | 3 | 2023 | 812 | 0.250 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 72 | 0.240 |
Why?
| | Remyelination | 1 | 2025 | 14 | 0.240 |
Why?
| | Multigene Family | 1 | 2005 | 198 | 0.230 |
Why?
| | Retrospective Studies | 9 | 2024 | 14404 | 0.230 |
Why?
| | Atrophy | 2 | 2021 | 170 | 0.210 |
Why?
| | Diphosphonates | 1 | 2003 | 56 | 0.210 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 66 | 0.210 |
Why?
| | Neuroprotection | 1 | 2023 | 34 | 0.210 |
Why?
| | Cellular Senescence | 1 | 2025 | 173 | 0.210 |
Why?
| | Myelin Sheath | 1 | 2025 | 161 | 0.210 |
Why?
| | Bone Resorption | 1 | 2003 | 80 | 0.210 |
Why?
| | Fatigue | 2 | 2024 | 316 | 0.210 |
Why?
| | Alemtuzumab | 1 | 2023 | 15 | 0.210 |
Why?
| | Microglia | 1 | 2025 | 228 | 0.200 |
Why?
| | Gadolinium | 2 | 2022 | 77 | 0.190 |
Why?
| | Inflammation | 1 | 2013 | 2646 | 0.190 |
Why?
| | Drug Costs | 1 | 2023 | 99 | 0.190 |
Why?
| | Neuroblastoma | 1 | 2023 | 153 | 0.190 |
Why?
| | Interoception | 1 | 2021 | 2 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2024 | 10110 | 0.190 |
Why?
| | Diagnostic Self Evaluation | 1 | 2021 | 22 | 0.190 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 569 | 0.190 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.190 |
Why?
| | Quality of Life | 4 | 2023 | 2672 | 0.180 |
Why?
| | Muscle, Skeletal | 5 | 2024 | 1620 | 0.180 |
Why?
| | Resistance Training | 1 | 2024 | 151 | 0.180 |
Why?
| | Hippocampus | 3 | 2002 | 801 | 0.180 |
Why?
| | Killer Cells, Natural | 2 | 2021 | 426 | 0.180 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 817 | 0.170 |
Why?
| | Lymphopenia | 1 | 2020 | 59 | 0.170 |
Why?
| | Personality | 1 | 2021 | 122 | 0.170 |
Why?
| | Interferon-gamma | 1 | 2023 | 760 | 0.170 |
Why?
| | Torso | 1 | 2020 | 30 | 0.170 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2002 | 92 | 0.160 |
Why?
| | Cancer Vaccines | 1 | 2021 | 163 | 0.160 |
Why?
| | Neutropenia | 1 | 2020 | 134 | 0.160 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 21 | 0.160 |
Why?
| | Disease Management | 1 | 2023 | 583 | 0.160 |
Why?
| | Muscle Strength | 2 | 2024 | 304 | 0.160 |
Why?
| | Pelvis | 1 | 2020 | 101 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 210 | 0.160 |
Why?
| | Sodium Glutamate | 1 | 1999 | 9 | 0.160 |
Why?
| | Receptors, Glutamate | 1 | 1999 | 21 | 0.160 |
Why?
| | Double-Blind Method | 5 | 2022 | 1852 | 0.150 |
Why?
| | Nerve Net | 1 | 2021 | 256 | 0.150 |
Why?
| | Avoidance Learning | 1 | 1999 | 67 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 85 | 0.150 |
Why?
| | Young Adult | 5 | 2021 | 12282 | 0.150 |
Why?
| | Muscle Spasticity | 1 | 2018 | 55 | 0.150 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 295 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 251 | 0.140 |
Why?
| | Dendritic Cells | 1 | 2021 | 475 | 0.140 |
Why?
| | Electric Stimulation Therapy | 1 | 2018 | 58 | 0.140 |
Why?
| | Gait | 1 | 2020 | 277 | 0.140 |
Why?
| | Reaction Time | 1 | 1999 | 406 | 0.140 |
Why?
| | Postural Balance | 1 | 2019 | 197 | 0.140 |
Why?
| | Interferon beta-1a | 1 | 2016 | 12 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4853 | 0.140 |
Why?
| | Psychomotor Performance | 1 | 2019 | 311 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 409 | 0.130 |
Why?
| | Disease Progression | 5 | 2022 | 2598 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2023 | 815 | 0.130 |
Why?
| | Transcription Factor RelA | 1 | 2016 | 79 | 0.130 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1096 | 0.130 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 89 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 755 | 0.130 |
Why?
| | CD40 Antigens | 1 | 2016 | 88 | 0.130 |
Why?
| | Contrast Media | 1 | 2018 | 387 | 0.120 |
Why?
| | Movement | 3 | 2023 | 269 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 858 | 0.120 |
Why?
| | Survival Analysis | 1 | 2018 | 1262 | 0.120 |
Why?
| | Pyridines | 1 | 2018 | 474 | 0.120 |
Why?
| | Postpartum Period | 1 | 2017 | 331 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 304 | 0.120 |
Why?
| | Neurons | 3 | 2011 | 1445 | 0.110 |
Why?
| | Melanoma | 1 | 2021 | 722 | 0.110 |
Why?
| | Disability Evaluation | 4 | 2018 | 285 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2021 | 818 | 0.110 |
Why?
| | Pain, Intractable | 1 | 2012 | 11 | 0.100 |
Why?
| | Pain | 1 | 2018 | 748 | 0.100 |
Why?
| | Rats | 5 | 2005 | 5199 | 0.100 |
Why?
| | Dopamine | 2 | 2005 | 285 | 0.090 |
Why?
| | Time Factors | 2 | 2021 | 6479 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 37 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.090 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 150 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 390 | 0.090 |
Why?
| | Neoplasms | 1 | 2024 | 2460 | 0.080 |
Why?
| | Animals | 8 | 2025 | 34487 | 0.080 |
Why?
| | Aged | 5 | 2024 | 21892 | 0.080 |
Why?
| | Adolescent | 4 | 2021 | 20158 | 0.080 |
Why?
| | Leukocytes | 1 | 2011 | 303 | 0.080 |
Why?
| | Lymphocytes | 1 | 2011 | 367 | 0.080 |
Why?
| | Pregnancy | 2 | 2018 | 6355 | 0.080 |
Why?
| | Immunoglobulin G | 2 | 2023 | 842 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2013 | 3324 | 0.080 |
Why?
| | Spinal Cord | 2 | 2012 | 353 | 0.070 |
Why?
| | Biomechanical Phenomena | 2 | 2021 | 759 | 0.070 |
Why?
| | MicroRNAs | 1 | 2013 | 674 | 0.070 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 251 | 0.060 |
Why?
| | Microinjections | 3 | 2002 | 76 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2019 | 341 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 50 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 150 | 0.060 |
Why?
| | Pilot Projects | 2 | 2021 | 1559 | 0.060 |
Why?
| | Chemokine CCL11 | 1 | 2025 | 25 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 290 | 0.060 |
Why?
| | Cytoplasm | 1 | 2005 | 257 | 0.060 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2005 | 145 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 9696 | 0.060 |
Why?
| | Species Specificity | 1 | 2005 | 568 | 0.060 |
Why?
| | Electric Stimulation | 2 | 2021 | 268 | 0.060 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2003 | 24 | 0.050 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2004 | 73 | 0.050 |
Why?
| | Models, Biological | 1 | 2011 | 1689 | 0.050 |
Why?
| | Osteolysis | 1 | 2003 | 17 | 0.050 |
Why?
| | Nerve Growth Factors | 1 | 2004 | 73 | 0.050 |
Why?
| | Mice | 3 | 2025 | 16574 | 0.050 |
Why?
| | Aging | 2 | 2025 | 1745 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5034 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 755 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 1984 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2025 | 166 | 0.050 |
Why?
| | Pluripotent Stem Cells | 1 | 2004 | 78 | 0.050 |
Why?
| | Crotonates | 1 | 2022 | 4 | 0.050 |
Why?
| | Toluidines | 1 | 2022 | 6 | 0.050 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2022 | 3 | 0.050 |
Why?
| | Hydroxybutyrates | 1 | 2022 | 11 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2005 | 579 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1088 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2022 | 27 | 0.050 |
Why?
| | Histamine | 1 | 1982 | 65 | 0.050 |
Why?
| | Arm | 1 | 2023 | 106 | 0.050 |
Why?
| | Maze Learning | 1 | 2002 | 93 | 0.050 |
Why?
| | Behavior, Animal | 2 | 2002 | 485 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 125 | 0.050 |
Why?
| | Cell Division | 1 | 2003 | 777 | 0.050 |
Why?
| | Nitriles | 1 | 2022 | 159 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 457 | 0.050 |
Why?
| | Base Sequence | 1 | 2005 | 2134 | 0.050 |
Why?
| | Heart | 1 | 2005 | 637 | 0.050 |
Why?
| | MART-1 Antigen | 1 | 2021 | 12 | 0.050 |
Why?
| | Gray Matter | 1 | 2022 | 82 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 145 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 285 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 608 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 443 | 0.050 |
Why?
| | Research Report | 1 | 2021 | 73 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2820 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1073 | 0.040 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 200 | 0.040 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 182 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 58 | 0.040 |
Why?
| | Neuroimaging | 1 | 2022 | 278 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 307 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 860 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 332 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 51 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 601 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 513 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2019 | 150 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 90 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 70 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1681 | 0.040 |
Why?
| | Proteomics | 1 | 2025 | 1008 | 0.040 |
Why?
| | Hand | 1 | 2019 | 153 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 73 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1199 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 142 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 605 | 0.040 |
Why?
| | Leg | 1 | 2019 | 236 | 0.040 |
Why?
| | Knee Joint | 1 | 2021 | 367 | 0.040 |
Why?
| | Headache | 1 | 2018 | 137 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1288 | 0.030 |
Why?
| | Macrophages | 1 | 2025 | 1460 | 0.030 |
Why?
| | Organ Size | 1 | 2018 | 440 | 0.030 |
Why?
| | Internet | 1 | 2021 | 613 | 0.030 |
Why?
| | Memory | 1 | 1999 | 232 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1826 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1356 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 196 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 366 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2003 | 3168 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 1896 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 163 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5378 | 0.030 |
Why?
| | Risk | 1 | 2017 | 850 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5268 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2425 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2614 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 3766 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1012 | 0.030 |
Why?
| | Genetic Markers | 1 | 2013 | 338 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2041 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1473 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1681 | 0.020 |
Why?
| | Prospective Studies | 1 | 2024 | 7035 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 5688 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 419 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 630 | 0.020 |
Why?
| | Pain Measurement | 1 | 2012 | 478 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 973 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 317 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1290 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1934 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7029 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2703 | 0.010 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2004 | 16 | 0.010 |
Why?
| | Cell Shape | 1 | 2004 | 55 | 0.010 |
Why?
| | Mesencephalon | 1 | 2004 | 66 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 108 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 105 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 225 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 165 | 0.010 |
Why?
| | Grooming | 1 | 1982 | 6 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 28 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2004 | 155 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1982 | 362 | 0.010 |
Why?
| | Astrocytes | 1 | 2004 | 188 | 0.010 |
Why?
| | Oligonucleotides, Antisense | 1 | 2002 | 106 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 123 | 0.010 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2002 | 112 | 0.010 |
Why?
| | United States | 1 | 2018 | 13785 | 0.010 |
Why?
| | Locomotion | 1 | 1982 | 98 | 0.010 |
Why?
| | Catheterization | 1 | 2002 | 171 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1047 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1169 | 0.010 |
Why?
| | Action Potentials | 1 | 2002 | 468 | 0.010 |
Why?
| | Parkinson Disease | 1 | 2004 | 460 | 0.010 |
Why?
| | Gene Expression | 1 | 2002 | 1454 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2337 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4006 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 3039 | 0.010 |
Why?
|
|
Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|